SBI Securities’s BioXcel Therapeutics BTAI Stock Holding History

SBI Securities’s Portfolio BTAI Stock Details BTAI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$18	Sell	13 -1	-7%	-$1	﹤0.01%	3863
2026 Q1	$19	Sell	14 -155	-92%	-$255	﹤0.01%	3770
2025 Q4	$270	Hold	169	–	–	﹤0.01%	3113
2025 Q3	$433	Sell	169 -710	-81%	-$2.24K	﹤0.01%	3027
2025 Q2	$1.59K	Buy	879 +28	+3%	+$46	﹤0.01%	2489
2025 Q1	$1.73K	Buy	851 +57	+7%	+$213	﹤0.01%	2355
2024 Q4	$4.75K	Buy	+794	New	+$6.63K	﹤0.01%	1940

Other funds holding BTAI

DWM

Diversify Wealth Management Sandy, Utah $5.98B AUM 29.21% 1-Year Est. Return

Citigroup New York $303B AUM 53.02% 1-Year Est. Return

WTA

Washington Trust Advisors Wellesley, Massachusetts $1.35B AUM 28.4% 1-Year Est. Return

EWA

EverSource Wealth Advisors Birmingham, Alabama $2.97B AUM 28.74% 1-Year Est. Return

FFA

Farther Finance Advisors San Francisco, California $12.8B AUM 26.53% 1-Year Est. Return

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

TCM

Triumph Capital Management Denver, Colorado $552M AUM 20.75% 1-Year Est. Return

SBI Securities's BTAI Position: Q2 2026 in Review

SBI Securities reduced its BioXcel Therapeutics (BTAI) stake by 7.1% in Q2 2026, selling an estimated $1 and leaving 13 shares worth $18. The position accounts for ﹤0.01% of the portfolio, ranked #3863.

SBI Securities first reported a position in BTAI in Q4 2024 and has held it in 7 quarters since. The position peaked at $4.75K in Q4 2024. 8 funds tracked by Wall St. Rank hold BTAI as of Q2 2026.

SBI Securities held 13 shares of BioXcel Therapeutics worth $18 as of Q2 2026.
SBI Securities sold 1 BioXcel Therapeutics share in Q2 2026, an estimated $1.
BioXcel Therapeutics made up ﹤0.01% of SBI Securities's portfolio in Q2 2026, its #3863 holding.
SBI Securities first reported a position in BioXcel Therapeutics in Q4 2024 and has held it in 7 quarters since.
SBI Securities's BioXcel Therapeutics position peaked at $4.75K in Q4 2024.
8 funds tracked by Wall St. Rank held BioXcel Therapeutics as of Q2 2026.

Based on SBI Securities's 13F filing for Q2 2026, filed 23 Jul 2026.